• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs.

作者信息

Khvorova Anastasia

机构信息

From RNA Therapeutics Institute, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester.

出版信息

N Engl J Med. 2017 Jan 5;376(1):4-7. doi: 10.1056/NEJMp1614154.

DOI:10.1056/NEJMp1614154
PMID:28052224
Abstract
摘要

相似文献

1
Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs.寡核苷酸疗法——一类新型降胆固醇药物。
N Engl J Med. 2017 Jan 5;376(1):4-7. doi: 10.1056/NEJMp1614154.
2
Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.修饰的反义寡核苷酸和小干扰RNA作为抗病毒药物的应用。
Future Med Chem. 2015;7(13):1637-42. doi: 10.4155/fmc.15.114. Epub 2015 Sep 18.
3
Development of siRNA Therapeutics for the Treatment of Liver Diseases.用于治疗肝脏疾病的 siRNA 疗法的开发。
Methods Mol Biol. 2021;2282:57-75. doi: 10.1007/978-1-0716-1298-9_5.
4
Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.与新型非核苷三价N-乙酰半乳糖胺偶联的小干扰RNA（siRNA）的肝细胞特异性递送在体内引发了强大的基因沉默。
Chembiochem. 2015 Apr 13;16(6):903-8. doi: 10.1002/cbic.201500023. Epub 2015 Mar 18.
5
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.新型靶向肝细胞的GalNAc-siRNA偶联物的临床概念验证
Mol Ther. 2017 Jan 4;25(1):71-78. doi: 10.1016/j.ymthe.2016.10.019.
6
RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.癌症临床试验中的 RNA 靶向治疗药物：现状与未来方向。
Cancer Treat Rev. 2016 Nov;50:35-47. doi: 10.1016/j.ctrv.2016.08.004. Epub 2016 Aug 28.
7
N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases.N-乙酰半乳糖胺靶向治疗：为核苷酸类药物在心血管疾病中的临床应用铺平道路。
Arterioscler Thromb Vasc Biol. 2021 Dec;41(12):2855-2865. doi: 10.1161/ATVBAHA.121.316290. Epub 2021 Oct 14.
8
RNA-Targeted Therapeutics.RNA 靶向治疗药物。
Cell Metab. 2018 Apr 3;27(4):714-739. doi: 10.1016/j.cmet.2018.03.004.
9
Alnylam's RNAi therapy targets amyloid disease.阿尔尼拉姆公司的RNA干扰疗法针对淀粉样变性疾病。
Nat Biotechnol. 2015 Jun;33(6):577. doi: 10.1038/nbt0615-577a.
10
Targeting Therapeutic Oligonucleotides.靶向治疗性寡核苷酸
N Engl J Med. 2017 Jan 5;376(1):86-88. doi: 10.1056/NEJMcibr1613559.

引用本文的文献

1
How to measure and model cardiovascular aging.如何测量和模拟心血管衰老。
Cardiovasc Res. 2025 Aug 28;121(10):1489-1508. doi: 10.1093/cvr/cvaf138.
2
Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.inclisiran治疗基因确诊的纯合子家族性高胆固醇血症青少年的疗效和安全性：ORION-13随机试验双盲、安慰剂对照部分的结果
Circulation. 2025 Jun 24;151(25):1758-1766. doi: 10.1161/CIRCULATIONAHA.124.073233. Epub 2025 May 20.
3
Modern therapy of patients with lupus erythematosus must include appropriate management of their heightened rates of atherosclerotic cardiovascular events: a literature update.
红斑狼疮患者的现代治疗必须包括对其动脉粥样硬化性心血管事件高发生率的适当管理：文献综述。
Lupus Sci Med. 2025 Apr 8;12(1):e001160. doi: 10.1136/lupus-2024-001160.
4
Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials.inclisiran在心血管疾病中的当前应用：当前临床试验概述
Front Pharmacol. 2025 Feb 14;16:1449712. doi: 10.3389/fphar.2025.1449712. eCollection 2025.
5
Association between inclisiran and the risk of arrhythmias.英克西兰与心律失常风险之间的关联。
Int J Cardiol Heart Vasc. 2025 Jan 7;56:101591. doi: 10.1016/j.ijcha.2024.101591. eCollection 2025 Feb.
6
efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney.全身性给予丝氨醇核酸修饰的反义寡核苷酸在小鼠肾脏中的疗效和安全性。
Mol Ther Nucleic Acids. 2024 Dec 18;36(1):102387. doi: 10.1016/j.omtn.2024.102387. eCollection 2025 Mar 11.
7
Efficacy and Safety of PSCK9 Inhibitors on Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂对急性冠状动脉综合征患者的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
Rev Cardiovasc Med. 2024 Mar 7;25(3):94. doi: 10.31083/j.rcm2503094. eCollection 2024 Mar.
8
Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review.急性冠状动脉综合征中使用非他汀类降脂药物早期管理血脂水平：一篇综述
Cardiovasc Drugs Ther. 2024 Jun 29. doi: 10.1007/s10557-024-07587-9.
9
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.依洛尤单抗治疗强效且持久降低 LDL-C：ORION-8 试验。
Cardiovasc Res. 2024 Oct 14;120(12):1400-1410. doi: 10.1093/cvr/cvae109.
10
Chemically modified microRNA delivery via DNA tetrahedral frameworks for dental pulp regeneration.通过 DNA 四面体型框架递呈化学修饰的 microRNA 以实现牙髓再生。
J Nanobiotechnology. 2024 Apr 4;22(1):150. doi: 10.1186/s12951-024-02393-9.